Overview A Study of ALKS 3831 in Adults With Schizophrenia Status: Completed Trial end date: 2015-03-01 Target enrollment: Participant gender: Summary This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits. Phase: Phase 2 Details Lead Sponsor: Alkermes, Inc.Treatments: ALKS-33NaltrexoneOlanzapine